FindTrial
Sign In

Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis

Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis - Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026182
Enrollment
40
Registered
2017-02-16
Start date
2017-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients(two weeks) the bath additive without sweat-antigen-inactivating and moisturizing ingredients(two wee

Sponsors

Hiroshima Umiversity Hospital
Lead Sponsor
Hiroshima Prefectural Hospital JA Onomichi General Hospital JA Hiroshima General Hospital Tanaka dermatology and allergy clinic Mihara dermatology and allergy clinic Hiroshima City Asa Citizens Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with atopic dermatitis, whose treatment is no change within one month. 2.Patients who are 16 years old or older. 3.Patients who can visit our clinic reguraly. 4.Patients who can agree in writing to this study.

Exclusion criteria

Exclusion criteria: 1. Patients who have unstable symptoms. 2. Patients who are treated with oral steroids and/or cyclosporine. 3.Patients who have history of hypersensitivity reactions to bath additive, cosmetics, food or etc. 4.Patients who use a product having the purpose of use like examination bath additive. 5.Patients judged inappropriate for this study by the physicians.

Design outcomes

Primary

MeasureTime frame
VAS for itch—

Secondary

MeasureTime frame
Subjective symptom(disease questionnaire) Clinical condition(objective symptom: medical examination at the department of dermatology) Total assessment Safety—

Countries

Japan

Contacts

Public ContactAkiko Kamegashira

Hiroshima University, Hiroshima, Japan Department of Dermatology

kamegash@yahoo.co.jp082-257-5238

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026